Tango Therapeutics, Inc.

The capital markets continue to shy away from relatively risky investments, such as drug development, providing new funding for a limited number of companies. That means a lot of biopharmaceutical fir

Novartis AG outlined the details of its spin-off plans for its generics and biosimilars business Sandoz on 18 August, revealing the financial terms for the big pharma’s shareholders and the date of t

Adding patient-reported outcomes data to clinician-reported adverse events in early cancer drug trials could better inform dose selection and optimization, US Food and Drug Administration officials sa

In retrospect, 2021 was a surprising year for venture investment in the life sciences. Despite soaring COVID-19 cases – especially towards the end of the year due to the Omicron variant – wide-ranging